A Placebo-Controlled Study on the Effects of the Glucagon-Like Peptide-1 Mimetic, Exenatide, on Insulin Secretion, Body Composition and Adipokines in Obese, Client-Owned Cats

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

A Placebo-Controlled Study on the Effects of the Glucagon-Like Peptide-1 Mimetic, Exenatide, on Insulin Secretion, Body Composition and Adipokines in Obese, Client-Owned Cats. / Hoelmkjaer, Kirsten M.; Albrechtsen, Nicolai Jacob Wewer; Holst, Jens Juul; Cronin, Anna M.; Nielsen, Dorte H.; Mandrup-Poulsen, Thomas; Bjørnvad, Charlotte Reinhard.

In: P L o S One, Vol. 11, No. 5, e0154727, 02.05.2016.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Hoelmkjaer, KM, Albrechtsen, NJW, Holst, JJ, Cronin, AM, Nielsen, DH, Mandrup-Poulsen, T & Bjørnvad, CR 2016, 'A Placebo-Controlled Study on the Effects of the Glucagon-Like Peptide-1 Mimetic, Exenatide, on Insulin Secretion, Body Composition and Adipokines in Obese, Client-Owned Cats', P L o S One, vol. 11, no. 5, e0154727. https://doi.org/10.1371/journal.pone.0154727

APA

Hoelmkjaer, K. M., Albrechtsen, N. J. W., Holst, J. J., Cronin, A. M., Nielsen, D. H., Mandrup-Poulsen, T., & Bjørnvad, C. R. (2016). A Placebo-Controlled Study on the Effects of the Glucagon-Like Peptide-1 Mimetic, Exenatide, on Insulin Secretion, Body Composition and Adipokines in Obese, Client-Owned Cats. P L o S One, 11(5), [e0154727]. https://doi.org/10.1371/journal.pone.0154727

Vancouver

Hoelmkjaer KM, Albrechtsen NJW, Holst JJ, Cronin AM, Nielsen DH, Mandrup-Poulsen T et al. A Placebo-Controlled Study on the Effects of the Glucagon-Like Peptide-1 Mimetic, Exenatide, on Insulin Secretion, Body Composition and Adipokines in Obese, Client-Owned Cats. P L o S One. 2016 May 2;11(5). e0154727. https://doi.org/10.1371/journal.pone.0154727

Author

Hoelmkjaer, Kirsten M. ; Albrechtsen, Nicolai Jacob Wewer ; Holst, Jens Juul ; Cronin, Anna M. ; Nielsen, Dorte H. ; Mandrup-Poulsen, Thomas ; Bjørnvad, Charlotte Reinhard. / A Placebo-Controlled Study on the Effects of the Glucagon-Like Peptide-1 Mimetic, Exenatide, on Insulin Secretion, Body Composition and Adipokines in Obese, Client-Owned Cats. In: P L o S One. 2016 ; Vol. 11, No. 5.

Bibtex

@article{8997a2b32ce14afa81160f970a94bb38,
title = "A Placebo-Controlled Study on the Effects of the Glucagon-Like Peptide-1 Mimetic, Exenatide, on Insulin Secretion, Body Composition and Adipokines in Obese, Client-Owned Cats",
abstract = "Glucagon-like Peptide-1 mimetics increase insulin secretion and reduces body weight in humans. In lean, healthy cats, short-term treatment has produced similar results, whereas the effect in obese cats or with extended duration of treatment is unknown. Here, prolonged (12 weeks) treatment with the Glucagon-like Peptide-1 mimetic, exenatide, was evaluated in 12 obese, but otherwise healthy, client-owned cats. Cats were randomized to exenatide (1.0 μg/kg) or placebo treatment twice daily for 12 weeks. The primary endpoint was changes in insulin concentration; the secondary endpoints were glucose homeostasis, body weight, body composition as measured by dual-energy x-ray absorptiometry and overall safety. An intravenous glucose tolerance test (1 g/kg body weight) was conducted at week 0 and week 12. Exenatide did not change the insulin concentration, plasma glucose concentration or glucose tolerance (P>0.05 for all). Exenatide tended to reduce body weight on continued normal feeding. Median relative weight loss after 12 weeks was 5.1{\%} (range 1.7 to 8.4{\%}) in the exenatide group versus 3.2{\%} (range -5.3 to 5.7{\%}) in the placebo group (P = 0.10). Body composition and adipokine levels were unaffected by exenatide (P>0.05). Twelve weeks of exenatide was well-tolerated, with only two cases of mild, self-limiting gastrointestinal signs and a single case of mild hypoglycemia. The long-term insulinotropic effect of exenatide appeared less pronounced in obese cats compared to previous short-term studies in lean cats. Further investigations are required to fully elucidate the effect on insulin secretion, glucose tolerance and body weight in obese cats.",
author = "Hoelmkjaer, {Kirsten M.} and Albrechtsen, {Nicolai Jacob Wewer} and Holst, {Jens Juul} and Cronin, {Anna M.} and Nielsen, {Dorte H.} and Thomas Mandrup-Poulsen and Bj{\o}rnvad, {Charlotte Reinhard}",
year = "2016",
month = "5",
day = "2",
doi = "10.1371/journal.pone.0154727",
language = "English",
volume = "11",
journal = "P L o S One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "5",

}

RIS

TY - JOUR

T1 - A Placebo-Controlled Study on the Effects of the Glucagon-Like Peptide-1 Mimetic, Exenatide, on Insulin Secretion, Body Composition and Adipokines in Obese, Client-Owned Cats

AU - Hoelmkjaer, Kirsten M.

AU - Albrechtsen, Nicolai Jacob Wewer

AU - Holst, Jens Juul

AU - Cronin, Anna M.

AU - Nielsen, Dorte H.

AU - Mandrup-Poulsen, Thomas

AU - Bjørnvad, Charlotte Reinhard

PY - 2016/5/2

Y1 - 2016/5/2

N2 - Glucagon-like Peptide-1 mimetics increase insulin secretion and reduces body weight in humans. In lean, healthy cats, short-term treatment has produced similar results, whereas the effect in obese cats or with extended duration of treatment is unknown. Here, prolonged (12 weeks) treatment with the Glucagon-like Peptide-1 mimetic, exenatide, was evaluated in 12 obese, but otherwise healthy, client-owned cats. Cats were randomized to exenatide (1.0 μg/kg) or placebo treatment twice daily for 12 weeks. The primary endpoint was changes in insulin concentration; the secondary endpoints were glucose homeostasis, body weight, body composition as measured by dual-energy x-ray absorptiometry and overall safety. An intravenous glucose tolerance test (1 g/kg body weight) was conducted at week 0 and week 12. Exenatide did not change the insulin concentration, plasma glucose concentration or glucose tolerance (P>0.05 for all). Exenatide tended to reduce body weight on continued normal feeding. Median relative weight loss after 12 weeks was 5.1% (range 1.7 to 8.4%) in the exenatide group versus 3.2% (range -5.3 to 5.7%) in the placebo group (P = 0.10). Body composition and adipokine levels were unaffected by exenatide (P>0.05). Twelve weeks of exenatide was well-tolerated, with only two cases of mild, self-limiting gastrointestinal signs and a single case of mild hypoglycemia. The long-term insulinotropic effect of exenatide appeared less pronounced in obese cats compared to previous short-term studies in lean cats. Further investigations are required to fully elucidate the effect on insulin secretion, glucose tolerance and body weight in obese cats.

AB - Glucagon-like Peptide-1 mimetics increase insulin secretion and reduces body weight in humans. In lean, healthy cats, short-term treatment has produced similar results, whereas the effect in obese cats or with extended duration of treatment is unknown. Here, prolonged (12 weeks) treatment with the Glucagon-like Peptide-1 mimetic, exenatide, was evaluated in 12 obese, but otherwise healthy, client-owned cats. Cats were randomized to exenatide (1.0 μg/kg) or placebo treatment twice daily for 12 weeks. The primary endpoint was changes in insulin concentration; the secondary endpoints were glucose homeostasis, body weight, body composition as measured by dual-energy x-ray absorptiometry and overall safety. An intravenous glucose tolerance test (1 g/kg body weight) was conducted at week 0 and week 12. Exenatide did not change the insulin concentration, plasma glucose concentration or glucose tolerance (P>0.05 for all). Exenatide tended to reduce body weight on continued normal feeding. Median relative weight loss after 12 weeks was 5.1% (range 1.7 to 8.4%) in the exenatide group versus 3.2% (range -5.3 to 5.7%) in the placebo group (P = 0.10). Body composition and adipokine levels were unaffected by exenatide (P>0.05). Twelve weeks of exenatide was well-tolerated, with only two cases of mild, self-limiting gastrointestinal signs and a single case of mild hypoglycemia. The long-term insulinotropic effect of exenatide appeared less pronounced in obese cats compared to previous short-term studies in lean cats. Further investigations are required to fully elucidate the effect on insulin secretion, glucose tolerance and body weight in obese cats.

U2 - 10.1371/journal.pone.0154727

DO - 10.1371/journal.pone.0154727

M3 - Journal article

C2 - 27136422

VL - 11

JO - P L o S One

JF - P L o S One

SN - 1932-6203

IS - 5

M1 - e0154727

ER -

ID: 162605797